Roivant Sciences (ROIV) Accumulated Expenses (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Accumulated Expenses came in at $205.8 million in Q1 2026, up 80.08% YoY from $114.3 million in Q1 2025, and up 74.44% on a QoQ basis from $118.0 million in Q4 2025.
Roivant Sciences (ROIV) Accumulated Expenses (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Accumulated Expenses data on file, last reported at $205.8 million in Q1 2026.
- Quarterly Accumulated Expenses rose 80.08% year-over-year to $205.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $205.8 million (up 80.08% YoY) and the FY2026 annual result came in at $205.8 million, up 80.08% from the prior year.
- Accumulated Expenses rose to $205.8 million in Q1 2026, from $118.0 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $205.8 million in Q1 2026 to a low of $26.5 million in Q2 2025.
- A 5-year average of $93.1 million and a median of $108.3 million in 2025 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Accumulated Expenses soared 262.82% — and 2025, when it slumped 80.81%.
- Tracing ROIV's Accumulated Expenses over 5 years: stood at $41.9 million in 2022, then jumped by 83.46% to $76.9 million in 2023, then surged by 35.66% to $104.3 million in 2024, then increased by 13.1% to $118.0 million in 2025, then jumped by 74.44% to $205.8 million in 2026.
- The last three Accumulated Expenses figures came in at $205.8 million (Q1 2026), $118.0 million (Q4 2025), and $108.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 168.74 Mn |
| Mar 31, 2026 | 205.82 Mn |
| Dec 31, 2025 | 117.99 Mn |
| Sep 30, 2025 | 108.32 Mn |
| Jun 30, 2025 | 26.53 Mn |
| Mar 31, 2025 | 114.29 Mn |
| Dec 31, 2024 | 104.32 Mn |
| Sep 30, 2024 | 111.47 Mn |
| Jun 30, 2024 | 138.29 Mn |
| Mar 31, 2024 | 49.89 Mn |
| Dec 31, 2023 | 76.90 Mn |
| Sep 30, 2023 | 30.72 Mn |
| Jun 30, 2023 | 119.33 Mn |
| Mar 31, 2023 | 55.19 Mn |
| Dec 31, 2022 | 41.92 Mn |
| Sep 30, 2022 | 128.82 Mn |
| Jun 30, 2022 | 109.35 Mn |
| Mar 31, 2022 | 44.26 Mn |
| Dec 31, 2021 | 112.68 Mn |
| Sep 30, 2021 | 104.11 Mn |